Vancomycin: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Robert Badgett (Added External links) |
||
| Line 8: | Line 8: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
==External links== | |||
{{DailyMed|3625|vancomycin for injection}} | |||
[[Category:CZ Live]] [[Category:Health Sciences Workgroup]] | [[Category:CZ Live]] [[Category:Health Sciences Workgroup]] | ||
Revision as of 11:57, 6 January 2008
Adverse effects
Thrombocytopenia
Vancomycin may cause immune thrombocytopenia.[1]
Acute kidney injury
Vancomycin is associated with acute kidney injury if trough levels are above 15 microg/mL.[2] To avoid this, the blood levels of vancomycin should be monitored.[3][4]
References
- ↑ Von Drygalski A, Curtis BR, Bougie DW, et al (2007). "Vancomycin-induced immune thrombocytopenia". N. Engl. J. Med. 356 (9): 904–10. DOI:10.1056/NEJMoa065066. PMID 17329697. Research Blogging.
- ↑ Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006). "High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity". Arch. Intern. Med. 166 (19): 2138–44. DOI:10.1001/archinte.166.19.2138. PMID 17060545. Research Blogging.
- ↑ Welty TE, Copa AK (1994). "Impact of vancomycin therapeutic drug monitoring on patient care". Ann Pharmacother 28 (12): 1335–9. PMID 7696720. [e]
- ↑ Iwamoto T, Kagawa Y, Kojima M (2003). "Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin". Biol. Pharm. Bull. 26 (6): 876–9. PMID 12808304. [e]
External links
for injection 3625 - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).